New SCHWIND LASIK platform going strong at 6 months

Article

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

The multi-centric LASIK myopia study, conducted by Maria-Clara Arbelaez and colleagues, enrolled 358 eyes. Of all the eyes, 65% achieved a postoperative uncorrected visual acuity (UCVA) of 20/16 or better and 98% achieved a UCVA of 20/20 or better. Target refraction was also found to be good, with 96% of treated eyes falling into the ±0.5 D range.

Aberration-free treatments were also found to be very safe. More than 55% of eyes gained one or more lines of visual acuity after six months and the induction of higher order aberrations, compared with non-aspheric treatment, was minimal. The total RMS of postoperative higher order aberrations (for 6 mm analysis diameter) rose by an average of just 0.07 µm. This also resulted in higher contrast sensitivity for patients.

Importantly, good results were seen very shortly after treatment, with study participants attaining the same visual acuity as the preoperative best corrected vision just one day after the procedure.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.